Caitong International Asset Management Co., LTD Nurix Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $134 Billion
- Q1 2025
A detailed history of Caitong International Asset Management Co., LTD transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 37 shares of NRIX stock, worth $430. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37
Previous 13
184.62%
Holding current value
$430
Previous $245,000
79.59%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
74.4MCall Options Held
56.9KPut Options Held
7.9K-
Black Rock Inc. New York, NY6.82MShares$79.4 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$64 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$51.4 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$47.2 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$46.3 Million4.63% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $549M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...